176 related articles for article (PubMed ID: 16886519)
1. [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].
Rovers JM; Dautzenberg PL; ter Bruggen JP
Tijdschr Gerontol Geriatr; 2006 Jul; 37(3):117-20. PubMed ID: 16886519
[TBL] [Abstract][Full Text] [Related]
2. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
3. A case study in the treatment of dementia with Lewy bodies.
Kaufer DI
Acta Psychiatr Scand; 2004 Jul; 110(1):73-5; discussion 75-6. PubMed ID: 15180783
[TBL] [Abstract][Full Text] [Related]
4. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine in Parkinson's disease dementia.
Chitnis S; Rao J
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
[TBL] [Abstract][Full Text] [Related]
6. When a Parkinson's disease patient starts to hallucinate.
Poewe W
Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of degenerative dementia disorders--who should be treated?].
Hasselbalch SG; Kampmann JP
Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M
No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening.
Goetz CG; Fan W; Leurgans S
Mov Disord; 2008 Aug; 23(11):1541-5. PubMed ID: 18567004
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
[TBL] [Abstract][Full Text] [Related]
12. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
Ballard C; Lane R; Barone P; Ferrara R; Tekin S
Int J Clin Pract; 2006 Jun; 60(6):639-45. PubMed ID: 16805745
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine in Parkinson's disease dementia.
Lalli S; Albanese A
Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Bullock R; Cameron A
Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
van Laar T; Postma AG; Drent M
Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
[No Abstract] [Full Text] [Related]
16. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Emre M; Poewe W; De Deyn PP; Barone P; Kulisevsky J; Pourcher E; van Laar T; Storch A; Micheli F; Burn D; Durif F; Pahwa R; Callegari F; Tenenbaum N; Strohmaier C
Clin Neuropharmacol; 2014; 37(1):9-16. PubMed ID: 24434526
[TBL] [Abstract][Full Text] [Related]
17. [Tactile hallucinations induced by trihexyphenidyl in a patient with Parkinson's disease].
Funakawa I; Jinnai K
Rinsho Shinkeigaku; 2005 Feb; 45(2):125-7. PubMed ID: 15782612
[TBL] [Abstract][Full Text] [Related]
18. [Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].
Diraoui S; van Melick EJ; Jansen PA
Ned Tijdschr Geneeskd; 2004 Nov; 148(48):2365-8. PubMed ID: 15615268
[TBL] [Abstract][Full Text] [Related]
19. Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
Wesnes KA; McKeith I; Edgar C; Emre M; Lane R
Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500
[TBL] [Abstract][Full Text] [Related]
20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
